Rett Syndrome: From the Involved Gene(s) to Treatment: From the Involved Gene(s) to Treatment

Charlotte Kilstrup Nielsen, Nicoletta Landsberger

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Rett syndrome (RTT) is a devastating genetic disorder that worldwide represents the most common genetic cause of severe intellectual disability in females. Most cases are caused by mutations in the X-linked MECP2 gene. The available molecular data suggest that MeCP2 is a key protein in brain and that its level and functions cannot be altered without severe consequences in both genders. Importantly, in 2007, new evidence indicated that RTT in principle is a reversible condition and that MeCP2-related disorders can be treated even at late stages of disease progression. However, in order to develop clinical applications, the functional role(s) of MeCP2 and their relevance for RTT pathobiology must be clearly understood. This chapter presents current knowledge of MeCP2 functions and its etiological role in disease development, the most promising therapeutic strategies and those that may be relevant in the future, and the challenges associated with treating RTT.

Original languageEnglish
Title of host publicationNeurobiology of Brain Disorders: Biological Basis of Neurological and Psychiatric Disorders
PublisherElsevier Inc.
Pages98-119
Number of pages22
ISBN (Print)9780123982803, 9780123982704
DOIs
Publication statusPublished - Dec 3 2014

Fingerprint

Rett Syndrome
Genes
X-Linked Genes
Inborn Genetic Diseases
Intellectual Disability
Disease Progression
Mutation
Brain
Proteins

Keywords

  • Chromatin structure
  • Epigenetics
  • MeCP2
  • MeCP2-related disorder
  • Molecular mechanism
  • Mouse model
  • Neural plasticity disorder
  • Rett syndrome
  • Therapeutic approach
  • Transcriptional regulation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Nielsen, C. K., & Landsberger, N. (2014). Rett Syndrome: From the Involved Gene(s) to Treatment: From the Involved Gene(s) to Treatment. In Neurobiology of Brain Disorders: Biological Basis of Neurological and Psychiatric Disorders (pp. 98-119). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-398270-4.00007-0

Rett Syndrome : From the Involved Gene(s) to Treatment: From the Involved Gene(s) to Treatment. / Nielsen, Charlotte Kilstrup; Landsberger, Nicoletta.

Neurobiology of Brain Disorders: Biological Basis of Neurological and Psychiatric Disorders. Elsevier Inc., 2014. p. 98-119.

Research output: Chapter in Book/Report/Conference proceedingChapter

Nielsen, CK & Landsberger, N 2014, Rett Syndrome: From the Involved Gene(s) to Treatment: From the Involved Gene(s) to Treatment. in Neurobiology of Brain Disorders: Biological Basis of Neurological and Psychiatric Disorders. Elsevier Inc., pp. 98-119. https://doi.org/10.1016/B978-0-12-398270-4.00007-0
Nielsen CK, Landsberger N. Rett Syndrome: From the Involved Gene(s) to Treatment: From the Involved Gene(s) to Treatment. In Neurobiology of Brain Disorders: Biological Basis of Neurological and Psychiatric Disorders. Elsevier Inc. 2014. p. 98-119 https://doi.org/10.1016/B978-0-12-398270-4.00007-0
Nielsen, Charlotte Kilstrup ; Landsberger, Nicoletta. / Rett Syndrome : From the Involved Gene(s) to Treatment: From the Involved Gene(s) to Treatment. Neurobiology of Brain Disorders: Biological Basis of Neurological and Psychiatric Disorders. Elsevier Inc., 2014. pp. 98-119
@inbook{d2b90d0d192345c796c43c29c392b897,
title = "Rett Syndrome: From the Involved Gene(s) to Treatment: From the Involved Gene(s) to Treatment",
abstract = "Rett syndrome (RTT) is a devastating genetic disorder that worldwide represents the most common genetic cause of severe intellectual disability in females. Most cases are caused by mutations in the X-linked MECP2 gene. The available molecular data suggest that MeCP2 is a key protein in brain and that its level and functions cannot be altered without severe consequences in both genders. Importantly, in 2007, new evidence indicated that RTT in principle is a reversible condition and that MeCP2-related disorders can be treated even at late stages of disease progression. However, in order to develop clinical applications, the functional role(s) of MeCP2 and their relevance for RTT pathobiology must be clearly understood. This chapter presents current knowledge of MeCP2 functions and its etiological role in disease development, the most promising therapeutic strategies and those that may be relevant in the future, and the challenges associated with treating RTT.",
keywords = "Chromatin structure, Epigenetics, MeCP2, MeCP2-related disorder, Molecular mechanism, Mouse model, Neural plasticity disorder, Rett syndrome, Therapeutic approach, Transcriptional regulation",
author = "Nielsen, {Charlotte Kilstrup} and Nicoletta Landsberger",
year = "2014",
month = "12",
day = "3",
doi = "10.1016/B978-0-12-398270-4.00007-0",
language = "English",
isbn = "9780123982803",
pages = "98--119",
booktitle = "Neurobiology of Brain Disorders: Biological Basis of Neurological and Psychiatric Disorders",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Rett Syndrome

T2 - From the Involved Gene(s) to Treatment: From the Involved Gene(s) to Treatment

AU - Nielsen, Charlotte Kilstrup

AU - Landsberger, Nicoletta

PY - 2014/12/3

Y1 - 2014/12/3

N2 - Rett syndrome (RTT) is a devastating genetic disorder that worldwide represents the most common genetic cause of severe intellectual disability in females. Most cases are caused by mutations in the X-linked MECP2 gene. The available molecular data suggest that MeCP2 is a key protein in brain and that its level and functions cannot be altered without severe consequences in both genders. Importantly, in 2007, new evidence indicated that RTT in principle is a reversible condition and that MeCP2-related disorders can be treated even at late stages of disease progression. However, in order to develop clinical applications, the functional role(s) of MeCP2 and their relevance for RTT pathobiology must be clearly understood. This chapter presents current knowledge of MeCP2 functions and its etiological role in disease development, the most promising therapeutic strategies and those that may be relevant in the future, and the challenges associated with treating RTT.

AB - Rett syndrome (RTT) is a devastating genetic disorder that worldwide represents the most common genetic cause of severe intellectual disability in females. Most cases are caused by mutations in the X-linked MECP2 gene. The available molecular data suggest that MeCP2 is a key protein in brain and that its level and functions cannot be altered without severe consequences in both genders. Importantly, in 2007, new evidence indicated that RTT in principle is a reversible condition and that MeCP2-related disorders can be treated even at late stages of disease progression. However, in order to develop clinical applications, the functional role(s) of MeCP2 and their relevance for RTT pathobiology must be clearly understood. This chapter presents current knowledge of MeCP2 functions and its etiological role in disease development, the most promising therapeutic strategies and those that may be relevant in the future, and the challenges associated with treating RTT.

KW - Chromatin structure

KW - Epigenetics

KW - MeCP2

KW - MeCP2-related disorder

KW - Molecular mechanism

KW - Mouse model

KW - Neural plasticity disorder

KW - Rett syndrome

KW - Therapeutic approach

KW - Transcriptional regulation

UR - http://www.scopus.com/inward/record.url?scp=84942102118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942102118&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-398270-4.00007-0

DO - 10.1016/B978-0-12-398270-4.00007-0

M3 - Chapter

AN - SCOPUS:84942102118

SN - 9780123982803

SN - 9780123982704

SP - 98

EP - 119

BT - Neurobiology of Brain Disorders: Biological Basis of Neurological and Psychiatric Disorders

PB - Elsevier Inc.

ER -